Datasets:
Inabia-AI
/
continued-pretraining-jsonl

Dataset card Data Studio Files
xet
 Community
1
text
stringlengths
1
5.46k
ARTICLE 8 INTELLECTUAL PROPERTY ............................................................................88
8.1 Ownership of Intellectual Property .....................................................................88
8.2 Control of Intellectual Property ..........................................................................89
8.3 Maintenance and Prosecution of Patents. ............................................................90
8.4 Enforcement of Patents ......................................................................................94
8.5 Biosimilar Applicants.........................................................................................96
8.6 Enforcement of a Party's Patents ........................................................................97
8.7 Invalidity or Unenforceability Defenses or Actions. ...........................................97
8.8 Infringement Claims by Third Parties .................................................................98
8.9 Third Party Rights ............................................................................................ 100
8.10 Product Trademarks ......................................................................................... 100
ARTICLE 9 CONFIDENTIALITY AND NON-DISCLOSURE ............................................. 101
9.1 Confidentiality Obligations .............................................................................. 101
9.2 Permitted Disclosures....................................................................................... 104
9.3 Additional Permitted Disclosures ..................................................................... 104
9.4 Use of Names. .................................................................................................. 105
9.5 Public Announcements ..................................................................................... 105
9.6 Publications ..................................................................................................... 105
9.7 Return of Confidential Information .................................................................. 107
ARTICLE 10 REPRESENTATIONS AND WARRANTIES .................................................. 107
10.1 Mutual Representations and Warranties ........................................................... 108
10.2 Additional Representations and Warranties of Calibr. ...................................... 108
10.3 Additional Covenants of Calibr. ....................................................................... 118
10.4 Data Privacy and Security ............................................................................... 120
10.5 Data Export ...................................................................................................... 121
10.6 Debarment ....................................................................................................... 121
10.7 DISCLAIMER OF WARRANTIES. ................................................................ 121
10.8 Anti-Bribery and Anti-Corruption Compliance................................................. 122
ARTICLE 11 INDEMNITY .................................................................................................... 122
11.1 Indemnification of Calibr. ................................................................................ 122
11.2 Indemnification of AbbVie............................................................................... 122
11.3 Indemnification Procedures. ............................................................................. 123
11.4 Special, Indirect and Other Losses.................................................................... 126
11.5 Insurance ......................................................................................................... 126
ARTICLE 12 TERM AND TERMINATION .......................................................................... 127
12.1 Term and Expiration. ....................................................................................... 127
12.2 Termination ..................................................................................................... 127
12.3 Rights in Bankruptcy........................................................................................ 130
12.4 Consequences of Termination .......................................................................... 130
12.5 AbbVie Rights in Lieu of Termination ............................................................. 134
12.6 Remedies ......................................................................................................... 135
12.7 Accrued Rights; Surviving Obligations ............................................................ 135
ARTICLE 13 MISCELLANEOUS ......................................................................................... 136
13.1 Force Majeure. ................................................................................................. 136
13.2 Export Control. ................................................................................................ 137
13.3 Assignment ...................................................................................................... 137
13.4 Severability ...................................................................................................... 138
13.5 Dispute Resolution ........................................................................................... 138
13.6 Governing Law ................................................................................................ 139
13.7 Notices ............................................................................................................. 139
13.8 Entire Agreement; Amendments ...................................................................... 140
13.9 English Language............................................................................................. 140
13.10 Equitable Relief ............................................................................................... 140
13.11 Specific Performance ....................................................................................... 141
13.12 Waiver and Non-Exclusion of Remedies .......................................................... 141
13.13 No Benefit to Third Parties............................................................................... 141
13.14 Further Assurance. ........................................................................................... 141
13.15 Relationship of the Parties. ............................................................................... 142
13.16 HSR Act Compliance ....................................................................................... 142
13.17 References ....................................................................................................... 142
13.18 Construction..................................................................................................... 142
13.19 Amendment and Restatement ........................................................................... 143
13.20 Performance by Affiliates ................................................................................ 143
13.21 Counterparts..................................................................................................... 143
Schedules
Schedule 1.72 CD19 Autoimmune Subplan
Schedule 1.80 CD19 Plan
Schedule 1.94 Corporate Names
Schedule 1.119 Existing Patent Schedule
Schedule 1.121 Existing Targets
Schedule 1.129 Failed Target Criteria
Schedule 1.139 FTE Rates
Schedule 1.149 In-License Schedule
Schedule 1.225 PRLR Switch Plan
Schedule 1.273 Target Research Plan
Schedule 1.273(a) PRLR Interim Research Plan
Schedule 2.3.2-a mRNA Work Plan
Schedule 2.3.2-b In-Situ Work Plan
Schedule 2.6.3 Key Personnel
Schedule 7.6.4 Example Royalty Calculations
Schedule 9.1.2 Form of Employee Non-Disclosure Agreement
Schedule 9.5 Press Release
Schedule 10.2.1 Initial Disclosure Schedules
Schedule 10.2.1(o) Federally Funded Inventions
Schedule 10.2.2 A&R Disclosure Schedules
Schedule 10.2.2(o) Federally Funded Inventions
Schedule 10.2.3 Representations and Warranties as of the CD19 Option Bringdown Date
Schedule 10.2.4 Representations and Warranties as of the Existing Target ROFN Bringdown Date
Schedule 10.2.5 Representations and Warranties as of the Platform Option Bringdown Date
Schedule 10.3.3 Scripps License Agreement Amendment
Schedule 13.5 Arbitration
AMENDED AND RESTATED LICENSE AGREEMENT
This Amended and Restated License Agreement (this "Agreement") is made and entered into as of September 29, 2023 (the "A&R Effective Date") by and between The Scripps Research Institute, a California nonprofit public benefit corporation located at 10550 North Torrey Pines Road, La Jolla, California 92037, as successor ...
RECITALS
WHEREAS, Calibr is engaged in translational research and the discovery and development, in each case for the public benefit, of biological pharmaceutical product candidates for the prevention, diagnosis or treatment of diseases through the use of its proprietary sCAR-T Platform (as defined below);
WHEREAS, Calibr owns and controls certain intellectual property rights with respect to the sCAR-T Platform in the Territory (as defined below);
WHEREAS, Calibr and AbbVie entered into that certain License Agreement dated June 21, 2018 (such date the "Original Execution Date" and such agreement, the "Original License Agreement"); and
WHEREAS, the Parties wish to amend and restate the Original License Agreement to, among other things, extend the exclusivity period with respect to the sCAR-T Platform and provide for Calibr to perform additional Development (as defined below) activities with respect to certain programs of interest to AbbVie.
NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:
ARTICLE 1 DEFINITIONS